Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug INCA036978 enters human testing for rare blood cancers

NCT ID NCT07441694

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This early-stage study tests an experimental drug, INCA036978, in about 218 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check the drug's safety and find the best dose, either alone or with standard treatment. Participants must have a life expectancy over 6 months and cannot have other recent cancers or serious infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Life expectancy \> 6 months. * Willingness to undergo a pretreatment and limited on-study BM biopsies and aspirates (as appropriate to disease). * Participants with MF, PV and ET as defined in the protocol. Exclusion Criteria: * Presence of any hematological malignancy other than MF, PV, or ET. * Malignancy within the last 3 years prior to enrollment. * Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection. * Clinically significant or uncontrolled cardiac disease. * Has undergone any prior allogeneic stem-cell transplantation or such transplantation is planned in the next 6 months. * Laboratory values outside the Protocol-defined ranges. * Prior history of major bleeding or thrombosis within the last 3 months prior to study enrollment. * Presence of chronic or current active infectious disease requiring systemic treatment. * Treatment with an MPN-directed therapy (approved or investigational) within the per protocol threshold before the administration of study drug. * Prior radiation therapy within 28 days before the first dose of study treatment. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelofibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloproliferative neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    54 sites in 11 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • A. Gemelli University Hospital, Catholic University of the Sacred Heart

    NOT_YET_RECRUITING

    Roma, 00168, Italy

  • AZ DELTA

    NOT_YET_RECRUITING

    Roeselare, 08800, Belgium

  • Aou Policlinico S. Orsola-Malpighi

    NOT_YET_RECRUITING

    Bologna, 40138, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale Asu Fc

    NOT_YET_RECRUITING

    Udine, 33100, Italy

  • Centre Hospitalier Universitaire (Chu) de Liege

    NOT_YET_RECRUITING

    Liège, 04000, Belgium

  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte

    NOT_YET_RECRUITING

    Berlin, 10117, Germany

  • City of Hope-Lennar Foundation Cancer Center

    NOT_YET_RECRUITING

    Irvine, California, 92618, United States

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Concord General Repatriation Hospital

    RECRUITING

    Concord, New South Wales, 02139, Australia

  • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy

    NOT_YET_RECRUITING

    Durham, North Carolina, 27705, United States

  • Ehime University Hospital

    NOT_YET_RECRUITING

    Toon, Ehime, 791-0204, Japan

  • Epworth Health Care

    RECRUITING

    East Melbourne, Victoria, 03002, Australia

  • Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico

    NOT_YET_RECRUITING

    Milan, 20122, Italy

  • Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust

    NOT_YET_RECRUITING

    London, SE1 9RT, United Kingdom

  • Hospital Saint Louis

    NOT_YET_RECRUITING

    Paris, 75010, France

  • Hospital Universitari Germans Trias I Pujol

    NOT_YET_RECRUITING

    Badalona, 08916, Spain

  • Hospital Universitario 12 de Octubre

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario de Gran Canaria Dr. Negrin

    NOT_YET_RECRUITING

    Las Palmas de Gran Canaria, 35010, Spain

  • Huntsman Cancer Institute

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84112, United States

  • Icon Cancer Centre

    RECRUITING

    Auchenflower, Queensland, 04066, Australia

  • Institut Bergonie

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    NOT_YET_RECRUITING

    Villejuif, 94805, France

  • John Hopkins Hospital

    NOT_YET_RECRUITING

    Baltimore, Maryland, 21287, United States

  • Levine Cancer Institute

    NOT_YET_RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 06009, Australia

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • McGill University Jewish General Hospital

    NOT_YET_RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Medical College of Wisconsin

    NOT_YET_RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Cancer Center

    NOT_YET_RECRUITING

    New York, New York, 10021, United States

  • Moffitt Cancer Center

    NOT_YET_RECRUITING

    Tampa, Florida, 33612, United States

  • Mount Sinai School of Medicine

    NOT_YET_RECRUITING

    New York, New York, 10029, United States

  • National Cancer Center Hospital East

    NOT_YET_RECRUITING

    Kashiwa Chiba, 277-0882, Japan

  • Nottingham University Hospitals

    NOT_YET_RECRUITING

    Nottingham, NG5 1PB, United Kingdom

  • Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Princess Margaret Cancer Center

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Royal North Shore Hospital

    RECRUITING

    St Leonards, New South Wales, 02065, Australia

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Jongno-gu, Seoul, 03080, South Korea

  • The Catholic University of Korea Seoul St. Mary'S Hospital

    NOT_YET_RECRUITING

    Seocho-gu, Seoul, 06591, South Korea

  • Tristar Bmt/Tcto

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • UCLA Medical Hematology & Oncology

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

  • Universitatklinikum Freiburg

    NOT_YET_RECRUITING

    Freiburg im Breisgau, 79106, Germany

  • Universitatsklinikum Halle (Saale)

    NOT_YET_RECRUITING

    Halle, 06120, Germany

  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

    NOT_YET_RECRUITING

    Mainz, 55131, Germany

  • University Medical Center Rwth Aachen

    NOT_YET_RECRUITING

    Aachen, D-52074, Germany

  • University of Alabama At Birmingham

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35233, United States

  • University of Miami

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • University of North Carolina At Chapel Hill

    NOT_YET_RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Oxford

    NOT_YET_RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • University of Texas M. D. Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Usc Norris Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90033, United States

  • Washington University School of Medicine

    NOT_YET_RECRUITING

    St Louis, Missouri, 63108, United States

  • Weill Cornell Medicine

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

  • Winship Cancer Institute of Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Yale Cancer Center

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.